Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
QLS5314 in Advanced Solid Tumors
NCT07915856Phase 1Not yet recruiting
- Sponsor
- Qilu Pharmaceutical
- Start
- Jan 2027
- Primary completion
- Oct 2029
01
Overview
Phase 1, open-label, single-arm trial of QLS5314 in solid tumor, sponsored by Qilu Pharmaceutical. Primary endpoints: Incidence and Severity of Adverse Events up to 2 years, Incidence of Dose-Limiting Toxicities at 21 days and 2 more. Planned start Jan 2027; status: not yet recruiting.
02
Drugs
QLS5314
03
Conditions
solid tumor
Beyond the preview
Go deeper on NCT07915856.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07915856.